Toward new horizons: The future of bisphosphonate therapy

Keyphrases

• Androgen Deprivation Therapy 40%
• Antitumor Activity 20%
• Bisphosphonate Therapy 100%
• Bisphosphonates 80%
• Bone Metastasis 20%
• Bone Mineral Density 20%
• Breast Cancer 40%
• Cancer Treatment-induced Bone Loss 60%
• Cincinnati 20%
• Clinical Benefit 20%
• Clinical Data 20%
• Clinical Trials 60%
• Clodronate 40%
• Disease Progression 20%
• Early Breast Cancer 20%
• Early Cancer 20%
• Estrogenic 20%
• Gambling 20%
• Hanover 20%
• High Risk 20%
• Hormonal Therapy 20%
• Malignant Bone Disease 40%
• Model Trial 20%
• Neoadjuvant Endocrine Therapy 20%
• Non-small Cell Lung Cancer (NSCLC) 20%
• Novartis 40%
• Oncology Setting 20%
• Patients with Breast Cancer 20%
• Placebo 20%
• Princeton 20%
• Prostate Cancer 60%
• Prostate Cancer Cells 20%
• Significant Benefit 20%
• Standard of Care 20%
• Treatment Duration 20%
• United Europe 20%
• United States 20%
• Zoledronic Acid 100%
• Zometa 40%

Pharmacology, Toxicology and Pharmaceutical Science

• Letrozole 14%
• Risedronic Acid 28%